

Pembrolizumab KEYNOTE-040

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Less serious adverse events observed


Other adjustments



Pembrolizumab KEYNOTE-040

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer
Therapeutic Indication: Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a $\geq 50\%$ TPS and progressing on or after platinum-containing ChT
Experimental Arm: Pembrolizumab
Control Arm: Standard of care (methotrexate, docetaxel or cetuximab)



